CompletedNCT00326391
Five doses of extended-release methylphenidate or placebo for adults with ADHD
About this title
A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder
Read the official source — NCT00326391Medication studyAges 18–65
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 229
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00326391
- Official title
Show the full official title
A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day.
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Did this study involve medication?
Yes. The study involved medication, including methylphenidate hydrochloride extended-release tablets.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD